Overall, tucatinib add-on to first-line maintenance therapy for HER2-positive metastatic breast cancer delayed progression by 8.6 months.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/adding-tucatinib-first-line-delays-progression-metastatic-2025a1000ywu?src=rss
Author :
Publish date : 2025-12-12 11:09:00
Copyright for syndicated content belongs to the linked Source.